Financial Performance - The company's operating revenue for the first half of 2023 was ¥161,285,944.35, representing a 46.22% increase compared to ¥110,302,755.90 in the same period last year[20]. - The net profit attributable to shareholders for the first half of 2023 was -¥29,611,147.98, an improvement from -¥71,234,762.46 in the previous year[20]. - The net cash flow from operating activities was ¥15,612,531.32, a significant recovery from -¥48,485,199.62 in the same period last year[20]. - The total assets at the end of the reporting period were ¥1,075,585,321.91, showing a slight increase of 0.75% from ¥1,067,613,744.66 at the end of the previous year[20]. - The net assets attributable to shareholders decreased by 2.63% to ¥824,799,496.61 from ¥847,084,284.58 at the end of the previous year[20]. - The company achieved total operating revenue of ¥161,285,944.35, an increase of 46.22% compared to the same period last year, primarily driven by a 57.19% increase in coronary intervention business revenue[21]. - The net profit attributable to the parent company was -¥29,611,147.98, a 58.43% increase year-on-year, while the net profit after deducting non-recurring gains and losses was -¥34,978,395.16, up 52.48% year-on-year[22]. - Basic and diluted earnings per share were both -¥0.07, reflecting a 58.82% improvement year-on-year, attributed to the increase in net profit[24]. - The company reported a net loss of CNY 224,710,563.35 in retained earnings compared to a loss of CNY 195,099,415.37 previously[187]. - The total operating revenue for the first half of 2023 reached ¥161,285,944.35, a significant increase from ¥110,302,755.90 in the same period of 2022, representing an increase of approximately 46.2%[194]. - The net loss for the first half of 2023 was ¥32,195,883.38, an improvement compared to a net loss of ¥74,620,619.86 in the first half of 2022, reflecting a reduction in losses of approximately 56.9%[195]. Research and Development - The proportion of R&D investment to operating revenue was 49.85%, a decrease of 47.15 percentage points compared to the same period last year, due to significant revenue growth and reduced R&D spending[24]. - The company achieved a cumulative R&D investment of 80.4 million yuan, accounting for 49.85% of its operating revenue[42]. - The company’s R&D investment totaled ¥80,397,586.14, a decrease of 24.86% compared to the previous year, primarily due to fewer projects and reduced costs in materials and services[52][53]. - Research and development expenses decreased to ¥52,417,509.01 from ¥81,243,778.86, showing a reduction of about 35.4%[194]. - The R&D personnel count decreased to 112, representing 18.06% of the total workforce, down from 26.26% in the previous year, indicating a strategic shift in resource allocation[68]. - The average salary for R&D personnel increased to 17.69 million RMB, compared to 14.52 million RMB in the previous year, reflecting the company's commitment to attracting and retaining talent[68]. - The company has filed 7 new invention patents and obtained 5 new patents during the reporting period[42]. - The company has established a fatigue micro-particle testing system to shorten testing cycles for coated stent products, enhancing product development efficiency[47]. Market and Product Development - The coronary intervention market is expected to continue growing rapidly, driven by increasing patient numbers and the implementation of centralized procurement policies[30]. - The neuro-interventional market in China is still in its early stages, with significant potential for domestic product innovation and market share growth[30]. - The company is focusing on expanding its product offerings in structural heart disease, which is a high-growth and high-value sector within the cardiovascular device market[30]. - Sino Medical has established an international-level R&D, production, and operation system, focusing on high-end interventional medical devices, with over 1.45 million units of key products used across more than 2,000 hospitals in China and other regions[32]. - The company’s new generation drug-eluting stent system, HT Supreme, is the world's first healing-oriented coronary drug-eluting stent system, with clinical studies conducted simultaneously in China, the US, Japan, and Europe[33]. - The intracranial balloon dilation catheter, Neuro RX, is the first to be approved by the National Medical Products Administration in China, utilizing rapid exchange technology for intracranial interventions[33]. - The NOVA drug-eluting stent system is the world's first specifically designed for treating intracranial artery stenosis, having passed special review for innovative medical devices in 2021[33]. - The company has developed a new intracranial thrombectomy stent (GHUNTER) aimed at removing ischemic cerebral thrombosis within 8 hours of symptom onset, targeting large intracranial vessels[36]. - The company has launched a new negative pressure suction pump (TORR) for general suction in hospitals and clinics, enhancing its product portfolio[36]. - The company has developed a distal access guiding catheter (NovaRail) for introducing interventional devices into the neurovascular and peripheral vascular systems[36]. - The company has established multiple self-developed production platforms, reinforcing its core competencies in interventional treatment technologies[38]. - The company has developed a new generation of magnesium alloy biodegradable stent systems, maintaining mechanical support for 3 to 6 months post-implantation[42]. - The company has obtained 20 domestic medical device registration certificates and 2 FDA (510k) certifications, expanding its product range significantly[43]. Risks and Challenges - The company has outlined various risks and countermeasures in its report, emphasizing the importance of investor awareness regarding investment risks[5]. - The report includes a forward-looking statement risk declaration, indicating that future plans and strategies do not constitute actual commitments to investors[6]. - The company faces risks related to new product development failures, talent retention, and the impact of centralized procurement policies on sales and profit margins[84][85][87]. - The company is exposed to supply risks for key raw materials, which are limited in availability and subject to various uncertainties[90]. - The company has a risk of continuous losses due to the impact of centralized procurement policies and high R&D expenses[93]. - The company faces risks related to the uncertainty of new product launches, which could delay revenue generation and impact cash flow[89]. Corporate Governance - The board of directors and management have confirmed the authenticity and completeness of the financial report, taking legal responsibility for its accuracy[4]. - The report is unaudited, and the company has not proposed any profit distribution or capital reserve transfer plans for this reporting period[8]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[7]. - The company has a diverse and experienced management team, with many members having backgrounds in multinational corporations, enhancing its operational capabilities[74]. - The company’s stock incentive plan has not seen any progress or changes since its last announcement[116]. - The company’s annual general meeting procedures were compliant with relevant laws and regulations[114]. - There were no changes in the company’s board of directors, supervisors, or senior management during the reporting period[115]. Environmental and Social Responsibility - The company has established mechanisms for environmental protection and regularly monitors emissions, with results meeting compliance standards[122]. - The company has invested 33.99 million yuan in environmental protection during the reporting period[120]. - There were no administrative penalties related to environmental issues during the reporting period[122]. - The company has not disclosed any new environmental information during the reporting period[122]. - The company has not implemented any carbon reduction measures during the reporting period[122].

赛诺医疗科学技术股份有限公司关于参加 2023 年半年度医疗器械专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （http://roadshow.sseinfo.com/） 证券代码：688108 证券简称：赛诺医疗 公告编号：2023-044 投资者可于 2023 年 09 月 04 日(星期四)17:00 前通过公司邮箱（ir@sinomed.com）、 投资者关系电话（010-80482240）、传真等方式将需要了解和关注的问题提前提供给 公司。公司将在文字互动环节对投资者普遍关注的问题进行回答。 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）于2023年8月 25日发布公司2023年半年度报告，为便于广大投资者更及时全面深入地了解公司2023年 半年度的经营成果、财务状况和发展理念，公司拟参与由上交所主办的2023半年度医疗 器械专场集体业绩说明会，此次活动将采用视频和网络文字互动的方式举行，投资者可 登录上海证券交易所上证路演中心（http://roads ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2023-043 赛诺医疗科学技术股份有限公司 赛诺医疗科学技术股份股份有限公司（以下简称"赛诺医疗"或"公司"） 于 2023 年 8 月 25 日在上海证券交易所网站（http://www.sse.com.cn）上披露 了《赛诺医疗科学技术股份有限公司 2023 年半年度报告》。 为加强与投资者的深入交流，便于广大投资者更全面深入地了解公司，在上 海证券交易所的支持下，公司计划于 2023 年 9 月 1 日下午 13:00-14:00 在上证 路演中心（http://roadshow.sseinfo.com）以网络文字互动问答的方式举行赛 诺医疗 2023 年半年度业绩说明会，与广大投资者进行充分交流，解答投资者普 遍关注的问题。 二、说明会召开的时间、地点 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 1、会议召开时间：2023 年 9 月 1 日下午 13:00-14:00 2、会议召开地点：上 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2023-042 赛诺医疗科学技术股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》以及《上海 证券交易所科创板上市公司自律监管指南》的规定，本公司将 2023 年上半年度募集 资金存放与使用情况专项说明如下： 一、募集资金基本情况 资金金额为 312,594,315.80 元，本期末募集资金账户余额 8,549,656.73 元，剩余 可用余额 8,549,656.73 元。 二、募集资金管理情况 （一）募集资金管理制度情况 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司监管指 引第 2 号—上市公司募集资金管理和使用的监管要求》《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》等相关规定的要求制定了《赛诺医疗科 学技术股份有限公司募 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2023-041 赛诺医疗科学技术股份有限公司 关于第二届监事会第十四次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）第二届监 事会第十四次会议通知于 2023 年 8 月 11 日以书面送达等方式通知各位监事。会议于 2023 年 8 月 23 日在北京市海淀区高梁桥斜街 59 号中坤大厦 7 层公司会议室以现场和 通讯相结合的方式召开。本次会议应出席监事 3 人，实际出席监事 3 人。本次会议由 监事会主席李天竹先生召集并主持，公司部分高管列席了本次会议。本次会议的召开 符合《中华人民共和国公司法》等有关法律、法规、规范性文件及《公司章程》《监事 会议事规则》等的规定，会议召开程序合法有效。 二、监事会会议审议情况 经与会监事认真讨论，审议并通过如下事项： 1、审议通过"关于赛诺医疗科学技术股份有限公司 2023 年半年度报告及其摘要 的议案" 经与会监事审议，一 ...

1、审议通过"关于赛诺医疗科学技术股份有限公司 2023 年半年度报告及其摘要 的议案" 证券代码：688108 证券简称：赛诺医疗 公告编号：2023-040 赛诺医疗科学技术股份有限公司 关于第二届董事会第十四次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）第二届董 事会第十四次会议通知于 2023 年 8 月 11 日以书面等方式送达各位董事和监事。会议 于 2023 年 8 月 23 日以现场和通讯相结合的方式在北京市海淀区高梁桥斜街 59 号中 坤大厦 7 层公司会议室召开。本次会议应出席董事 9 人，实际出席董事 9 人。本次会 议由董事长孙箭华先生召集并主持，公司监事、部分高管列席了本次会议。本次会议 的召开符合《中华人民共和国公司法》等有关法律、法规、规范性文件及《公司章程》 《董事会议事规则》等的规定，会议召开程序合法有效。 二、董事会会议审议情况 经与会董事认真讨论，审议并通过如下事项： 经与会董事审 ...

赛诺医疗科学技术股份有限公司 关于公司产品在海外获得注册批准的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）于 2023 年 3 月向泰国药监局递交了公司 SC HONKYTONK 冠脉球囊扩张导管的注册申报资料。公司 于近日收到泰国药监局通知，公司 SC HONKYTONK 冠脉球囊扩张导管获得泰国药监局批 准，获得《医疗器械注册证》。现将相关情况公告如下： 证券代码：688108 证券简称：赛诺医疗 公告编号：2023-039 一、《医疗器械注册批准文件》内容 注册证编号： 66-2-1-2-0010434 产品名称：冠脉球囊扩张导管 结构及组成型：冠脉球囊扩张导管为快速交换型（Rx）球囊扩张导管。主要由 TIP 头、球囊保护鞘、球囊、球囊内管、球囊外管、金属导管组成，球囊内有铂铱合金显影 环。产品经环氧乙烷灭菌，一次性使用，货架有效期 3 年。 适用范围：该产品适用于对冠状动脉的狭窄节段或搭桥狭窄部位进行球囊导管扩 张，以 ...

2023 年第一季度报告 证券代码：688108 证券简称：赛诺医疗 赛诺医疗科学技术股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人孙箭华、主管会计工作负责人沈立华及会计机构负责人（会计主管人员）李美红保证 季度报告中财务信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 1 / 16 单位：元 币种：人民币 项目 本报告期 本报告期比上年同期增减变动幅度(%) 营业收入 73,168,207.49 23.82 归属于上市公司股东的净利润 -16,208,533.57 不适用 归属于上市公司股东的扣除非经 常性损益的净利润 -20,275,952.81 不适用 经营活动产生的现金流量净额 -19,993,202.99 不适用 基本每股收益（元/股） ...

Financial Performance - Sino Medical reported no cash dividends for 2022 due to adverse impacts from the centralized procurement policy for coronary stents, prioritizing future development needs[6]. - The company did not achieve profitability at the time of its listing, indicating ongoing investment in product development and market expansion[5]. - The board of directors approved a profit distribution plan that reflects the company's current operational challenges and future funding requirements[6]. - Sino Medical's financial report received a standard unqualified audit opinion from its accounting firm, ensuring the accuracy of its financial statements[6]. - The company achieved total operating revenue of CNY 192,854,227.69 in 2022, a decrease of 0.77% compared to the previous year[26]. - The net profit attributable to shareholders was CNY -162,381,785.82, a decline of 24.18% year-on-year[26]. - The net cash flow from operating activities was CNY -111,312,741.89, down 85.11% compared to the previous year, primarily due to a decrease in revenue and delayed customer payments[27]. - Basic and diluted earnings per share were both CNY -0.40, a decrease of 25.00% from the previous year[24]. - The company's R&D expenditure accounted for 107.51% of operating revenue, an increase of 12.14 percentage points year-on-year[24]. - The gross profit margin decreased due to a significant drop in product prices and low capacity utilization[26]. - Total assets at the end of 2022 were CNY 1,067,613,744.66, a decrease of 3.22% from the previous year[23]. - The company's net assets attributable to shareholders were CNY 847,084,284.58, down 8.70% year-on-year[23]. Research and Development - Sino Medical is actively engaged in research and development of new products, particularly in the field of interventional medical devices[15]. - The company invested a total of 207 million RMB in R&D throughout the year, an increase of 11.86% year-on-year, accounting for 107.51% of the 2022 operating revenue[43]. - The company holds 185 global invention patents across various countries, enhancing its competitive edge in the market[43]. - The company launched three innovative products in the neurointervention field, establishing a leading position in this sector[42]. - The company has obtained 6 domestic medical device registration certificates and 1 FDA (510k) certification during the reporting period[43]. - The company published 4 papers in core journals, contributing to its reputation in the medical device industry[43]. - The company has established a comprehensive core technology system for interventional medical devices, focusing on cardiovascular and cerebrovascular diseases, supporting sustained business growth[105]. - The company has developed a series of specialized automated production equipment and operates over 25,000 square meters of R&D and production space, including a 9,000 square meter cleanroom[109]. Market Expansion and Strategy - The company is focused on expanding its market presence and enhancing its product offerings to meet growing healthcare demands[15]. - The company is advancing its internationalization strategy, with product registrations in over 10 countries including the USA, Europe, and Southeast Asia[50]. - The company is exploring opportunities for market expansion and potential mergers and acquisitions to enhance its competitive edge[55]. - The company aims to improve patient outcomes through advanced medical technologies and innovative product designs[55]. - The company is committed to maintaining high standards of product quality and regulatory compliance in all its markets[55]. - The company aims to continuously innovate and meet diverse clinical needs through sustained R&D investment and breakthrough innovations[67]. - The company is focusing on three key interventional treatment areas: coronary intervention, neuro intervention, and structural heart disease, to diversify its business[179]. - The company plans to accelerate its international strategy, including seeking innovation and collaboration globally, and enhancing its presence in overseas markets[180]. Operational Risks and Challenges - The company has outlined various operational risks in its annual report, emphasizing the importance of risk management strategies[5]. - The company faces risks of substantial revenue decline and continued losses due to high production costs and potential underperformance in sales volume[115]. - The company is at risk of new product development failures or delays, which could hinder revenue growth and profitability[116]. - The company may experience talent loss if it fails to provide competitive compensation and development opportunities, impacting its operational capabilities[117]. - The company is exposed to risks from centralized procurement policies leading to price reductions for its coronary and neuro-interventional products[120]. - The company reported a continuous loss in 2022, with ongoing risks of sustained losses in 2023 despite participation in procurement programs[128]. Product Portfolio and Innovation - The company has a diverse product portfolio including coronary stents, balloon catheters, and neurovascular devices, with several products being industry leaders both domestically and internationally[55]. - The company has developed a new generation of magnesium alloy biodegradable stents, which maintain mechanical support for 3 to 6 months post-implantation and fully degrade within one year[80]. - The company has established an automated intelligent technology platform to enhance production consistency and precision in testing data[80]. - The company has made significant breakthroughs in neuro intervention, with the world's first self-expanding drug-eluting stent entering clinical stages and completing clinical enrollment in February 2023[84]. - The company successfully entered two new products into the national coronary stent procurement program, achieving selection by over 1,000 hospitals, marking a significant milestone for its coronary stent products[184]. Financial Outlook and Projections - The company reported a significant increase in revenue, achieving a total of 1.5 billion in 2022, representing a growth of 20% year-over-year[200]. - The company has provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion[200]. - New product launches are expected to contribute an additional 300 million in revenue, with a focus on innovative medical technologies[200]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of 200 million earmarked for this purpose[200]. - The company aims to improve operational efficiency, targeting a reduction in costs by 5% through streamlined processes[200].

证券代码：688108 证券简称：赛诺医疗 公告编号：2023-024 一、 说明会类型 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 赛诺医疗科学技术股份有限公司 关于召开 2022 年度业绩说明会的公告 本次投资者说明会以视频直播和网络文字互动形式召开，公司将针对 2022 年度的 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围 内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （网址：http://roadshow.sseinfo.com/） 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）于 2023 年 4 月 27 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年 度经营成果、财务状况，公司计划于 2023 年 05 月 10 日下午 15:00-16:30 举行 2022 年 度业绩说明会，就投资者关心的问题进行交流。 会议召开时间：2023 年 05 月 10 日(星期三)下午 15:00-16 ...